Moreover, arterioportal shunting can exacerbate tumor hypoxia, which promotes immunosuppression and resistance to anti-angiogenic therapies, potentially diminishing the anti-tumor effects of TKIs and anti-PD-(L)1 immunotherapy (24–26). Here, CD274 is linked to neoplasm.